HSD17B10 and early-onset autosomal dominant Alzheimer disease: Almost 350,000 compounds were screenedin our high-throughput recombinantenzyme assay to identify inhibitors against 17β-HSD10, a therapeutictarget in Alzheimer’s disease and cancer.